Open access, medical economics journal. Publishing leading studies that determine the cost-effectiveness of treatment and high-quality economic assessments
Joined April 2009
- Tweets2.2K
- Following766
- Followers1.4K
- Likes213
Pinned Tweet
Thrilled to share an article I co-authored with the Editors-in-Chief of Taylor & Francis's #healtheconomics journals! We surveyed 200+ #HEOR experts to identify key topics for 2026-27.
Read the article to find out the results and the EiC's insightsπ bit.ly/4ca6tTZ
Cell and #genetherapies offer durable, sometimes curative benefitsβbut high costs mean payers are still catching up on innovative payment strategies. Elias Pittos & Joe DePinto explore how payers are navigating these challenges. π
bit.ly/4zCjr6p
#HEOR
New paper tackles a key challenge in #healtheconomics: evaluating diagnostics & medical devices with limited comparative data. The authors use #bladdercancer as a case study to demonstrate novel methodological approaches.
Read the article in full here π bit.ly/3TJy9ck
New research reveals the hidden workplace cost of #handeczema. Our study shows employers should prioritize early diagnosis & prevention of occupational hand eczema.
The impact is bigger than you think.
πbit.ly/4hgD4cz
#HEOR #medicaleconomics
ππ’π π‘π₯π’π π‘πππ ππ«ππ’ππ₯π
New #costeffectiveness analysis of xanomeline and trospium chloride as first-line #schizophrenia treatment from a US payer perspective.
Read more π bit.ly/4ikCFrQ
Just in case you missed it! Our latest editorial features insights from Editors-in-Chief and readers on the #healtheconomics topics that will be important through 2026-27. Access the full editorial here π bit.ly/4qH4o8a
#HEOR #medicaleconomics #pharmacoeconomics
Want to know which #HEOR topics will be important in 2026-27?
Read our latest editorial featuring expert opinions from the Editors-in-Chief and readers of Taylor & Francis's premier #healtheconomics journalsπ bit.ly/4qH4o8a
#pharmacoeconomics #AI #RWE #healthequity
Great example of how #graphicalabstracts amplify research impact!
This study examines the #healtheconomic impact of continuous vital sign monitoring. The visual summary makes findings accessible to #clinicians & #policymakers alike.
Check it out π bit.ly/4fRoZRV
Journal of Medical Economics retweeted
New publication π Real-world data, published in @JME_Journal, show outpatient vs inpatient cilta-cel administration reduced inpatient days in patients with R/R #MultipleMyeloma after β₯4 prior LoT (2.4 vs 6.6 days PPPM; aIRR, 0.37; p < 0.001), with similar TFI, OS, CRS, and ICANS between cohorts.
Learn more: multiplemyelomahub.com/typesβ¦
#myeloma #mmsm #MedNews #MedEd
Journal of Medical Economics retweeted
New pub alert: Impact of Crohnβs perianal fistulas on healthcare resource utilization: a US chart review study tandfonline.com/doi/full/10.β¦ @JME_Journal
πSubstantial HCRU burden among patients with CD perianal fistulas, indicating an unmet need for effective management strategies that promote long-term fistula healing to ultimately support reduced patient burden and HCRU
Want to stay at the forefront of #healtheconomics? Our new monthly newsletter, ππ©π¨ππ₯π’π π‘π π¨π§ ππππ₯ππ‘ πππ¨π§π¨π¦π’ππ¬, delivers:
β
Latest breakthrough studies
β
Emerging research trends
β
Expert insights shaping
πinvt.io/1lxbi1pqrjk
#pharmacoeconomics
Explore our latest review examining the impact of avoiding or delaying progression to metastatic castration-resistant #prostatecancer on quality of life, #mortality, and #economicoutcomes.
Click here to view the article in full π bit.ly/49FgyIe
Journal of Medical Economics retweeted
After months of hard work, our SCD-PED economic cost model manuscript is now officially published in @JME_Journal. The burden of pediatric AKI is tremendous at nearly $400,000 per hospitalization.
But our SCD-PED is estimated to save almost $70,000 per hospitalization.
tandfonline.com/doi/full/10.β¦
Our latest article examines πππ¨πππ's cost-effectiveness compared to other long-acting insulins, including glargine, detemir, and degludec. Discover the authors' findings by clicking the link π bit.ly/4higT5r
#diabetes #costeffectiveness #healtheconomics #HEOR
π¨ Available nowπ¨
Our latest review provides an essential insight into how #patientreportedoutcomemeasures can be included in #costeffectiveness models that inform #healthtechnologyassessments of non-oncology treatments.
Read it here π bit.ly/4pnKUo5
π’ πΉππππππππ
ππ
ππππ
Discover the impact of treatment failure for #migraine on lost earnings among #triptan non-responders in the general population of #Denmark. Click the link for the full article π bit.ly/4piFVoy
π¨ππ¨π° π¨π§π₯π’π§ππ¨
Our latest article evaluates the budgetary impact of pathways using cT1 versus SoC (liver biopsy or VCTE) to assign suspected #MASH patients to #resmetirom. Graphical abstract available below.
Click here for the full article π bit.ly/4g3dLJQ
π’ π±πππ πππππππππ
: Our latest article assesses the economic impact of #influenzavaccination across the #UAE and #Iraq. Click the link to access it in full.
πbit.ly/3K2tz3u
Congratulations to the authorsβit was lovely to collaborate with you. #HEOR
π’Recommended readπ’
"#Costeffectiveness of wastewater and environmental monitoring of #respiratorysyncytialvirus to guide universal infant immunoprophylaxis in #Canada"
Read the #plainlanguagesummary below or click here for the full article π bit.ly/45BQlb3
#HEOR
We're excited to announce that our website now features a multimedia section showcasing our #videoabstracts. Access this content hereπ bit.ly/4oJik05
We have also expanded the extenders we offer to include #podcasts, and #videoarticles. Get in touch to find out more.